Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection.
Journal: JHEP reports : innovation in hepatology
Published: July 28, 2023
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
Journal: The New England journal of medicine
Published: May 11, 2022
Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial.
Journal: Intensive care medicine
Published: July 13, 2021
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.
Journal: Open forum infectious diseases
Published: April 15, 2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: March 18, 2021
Correction to: Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.
Journal: Clinical drug investigation
Published: February 23, 2021
Compassionate Use of Remdesivir in Children With Severe COVID-19.
Journal: Pediatrics
Published: February 10, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Journal: The lancet. Gastroenterology & hepatology
Published: January 19, 2021
The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
Journal: Science translational medicine
Published: December 23, 2020
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: November 16, 2020
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
Journal: The Lancet. Child & adolescent health
Published: November 03, 2020
Last Updated: 09/26/2026